Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.

{"article_title":"Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.","author":"Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Inc\u00e0 R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S","journal_title":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","issn":"1878-3562","isbn":"","publication_date":"2017-06-01","volume":"49","issue":"6","first_page":"604","page_count":"","accession_number":"28254463","doi":"10.1016\/j.dld.2017.01.161","publisher":"Elsevier","doctype":"Journal Article","subjects":"Adrenal Cortex Hormones therapeutic use; Immunosuppressive Agents therapeutic use; Inflammatory Bowel Diseases drug therapy; Humans; Italy; Remission Induction; Societies, Medical","interest_area":["Gastroenterology"],"abstract":"The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn's disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases. Copyright \u00a9 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=28254463","isPdfLink":false,"isSAML":false,"an":"28254463","number_other":"","type_pub":"","issn_electronic":"1878-3562","languages":"English","language":"eng","date_entry":"Date Created: 20170304 Date Completed: 20180420 Latest Revision: 20220330","date_update":"20240104","titleSource":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2017 Jun; Vol. 49 (6), pp. 604-617. Date of Electronic Publication: 2017 Jan 25.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2017-06-01","description":"The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn's disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.<br \/> (Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=28254463&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Inc\u00e0 R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S"}